source
- GSK drops chronic cough drug camlipixant after mixed Phase 3 resultsGSK announced it will stop investing in camlipixant for refractory chronic cough after the drug failed to meet key endpoints in a late-stage trial. The company had run two Phase 3 studies, CALM-1…
- Insmed's inhaled PAH therapy shows durable efficacy in 12-month extension, bolstering $6B sales outlookInsmed reported that its inhalable prostanoid candidate, treprostinil palmitil inhalation powder (TPIP), maintained functional and biomarker benefits through a 12‑month open‑label extension in pati…